Plant-Derived Composition for Viral Respiratory Infection Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for preventing and treating viral respiratory infections are inadequate, particularly due to the rapid mutation of viruses, limited availability of effective vaccines, and side effects associated with antiviral drugs, necessitating a safe and cost-effective solution.
Innovation Solution
A composition comprising plant- or fungus-derived compounds such as D-Limonene, menthol, linalyl anthranilate, and others, formulated as dietary supplements or administered in various forms, to treat or prevent viral respiratory infections by enhancing immune response and reducing viral replication.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antiviral drugs are used to treat viral respiratory infections, then viral infection treatment effectiveness is improved, but side effects and safety concerns worsen
Solution Approach 1:
The patent employs natural compounds from plants and fungi as temporary, non-persistent therapeutic agents that provide antiviral activity without the long-term safety concerns associated with synthetic antiviral drugs. These natural compounds act as disposable-like interventions that resolve the infection without accumulating harmful side effects in the body.
Solution Approach 2:
The patent introduces natural compounds as intermediary substances between the virus and the host immune system. These compounds modulate the interaction by enhancing immune response and inhibiting viral replication, serving as a safe bridge that reduces the need for direct aggressive antiviral intervention.
2Reliability
If vaccines are developed to prevent viral respiratory infections, then infection prevention is improved, but development time and availability worsen
Solution Approach 1:
The patent applies preliminary action by using natural compounds that can be immediately administered to prevent viral infections before they occur. These compounds are ready for use without requiring the lengthy development and approval processes needed for vaccines, providing immediate preventive protection.
Solution Approach 2:
The patent utilizes readily available natural compounds as disposable preventive agents that can be immediately deployed without the time-consuming development cycle required for vaccines. These natural substances provide rapid, cost-effective prevention while avoiding the lengthy regulatory and development processes.
3Reliability
If synthetic antiviral compounds are used, then treatment efficacy is improved, but safety and cost-effectiveness worsen
Solution Approach 1:
The patent replaces expensive, potentially harmful synthetic antivirals with inexpensive, naturally derived compounds from plants and fungi. These natural compounds provide equivalent antiviral efficacy with improved safety profiles, acting as disposable-like therapeutic agents that resolve infections without significant adverse effects.
Solution Approach 2:
The patent converts the potentially harmful effect of viral infections into a beneficial response by using natural compounds that trigger protective immune responses. These compounds transform the infection challenge into an opportunity to enhance the host's natural defenses, converting a harmful situation into a beneficial immunological response.
Data Source
AI summary
The present invention relates to compositions comprising one or more plant- or fungus-derived compounds and their use for treating or preventing viral respiratory infections (VRIs), such as COVID-19.